Genome-wide progesterone receptor binding: cell type-specific and shared mechanisms in T47D breast cancer cells and primary leiomyoma cells

Progesterone, via its nuclear receptor (PR), exerts an overall tumorigenic effect on both uterine fibroid (leiomyoma) and breast cancer tissues, whereas the antiprogestin RU486 inhibits growth of these tissues through an unknown mechanism. Here, we determined the interaction between common or cell-s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2012-01, Vol.7 (1), p.e29021
Hauptverfasser:	Yin, Ping, Roqueiro, Damian, Huang, Lei, Owen, Jonas K, Xie, Anna, Navarro, Antonia, Monsivais, Diana, Coon, 5th, John S, Kim, J Julie, Dai, Yang, Bulun, Serdar E
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Base Sequence Binding sites Binding Sites - genetics Biology Breast cancer Breast Neoplasms - genetics Breast Neoplasms - metabolism Breast Neoplasms - pathology Cancer Cancer cells Cell growth Cell Line, Tumor Cell migration Chromatin E2F protein Endometrial cancer Estrogens Extracellular matrix Female Fibroids FOXO1 protein Gene expression Gene Expression Profiling Gene Expression Regulation, Neoplastic - drug effects Gene regulation Genes Genome, Human - genetics Genomes Genomics Heat shock proteins Hormone Antagonists - pharmacology Hormone replacement therapy Humans Leiomyoma Leiomyoma - genetics Leiomyoma - metabolism Leiomyoma - pathology Medicine Membrane Proteins - genetics Middle Aged Mifepristone - pharmacology Nucleotide Motifs - genetics Oligonucleotide Array Sequence Analysis Perilipin-2 Position-Specific Scoring Matrices Progesterone Receptors, Progesterone - metabolism Regulatory sequences Response Elements - genetics RNA Tissues Transcription Transcription (Genetics) Tumor Cells, Cultured Uterine cancer Uterine Neoplasms - genetics Uterine Neoplasms - metabolism Uterine Neoplasms - pathology Uterus Womens health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!